Denintuzumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Denintuzumab is a biosimilar that targets CD19
• CD19 is a member of the immunoglobulin superfamily and has two Ig like domains
• The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains
• CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage
• Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen
• The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias
• Lymphocytes proliferate and differentiate in response to various concentrations of different antigens
• The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors
• CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation
• Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge
• Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.